Organization | Kenyatta National Hospital

Kenyatta National Hospital Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial

2006

NCT00130910

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Kenyatta National Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Drugs in Other Trials (1)

albendazole (Albenza) (1 trial)

Indications

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 2